Genitourinary

<!-- Name:DistributionId Value:8828415 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

<!-- Name:DistributionId Value:8751346 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

Washington, D.C., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Facts and Factors has published a new research report titled “Genitourinary Drugs Market Size, Share, Growth Analysis Report By Product (Hormonal Therapy, Urological, and Others), By…

SAN FRANCISCO and SAN DIEGO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced the poster presentation of the design and rationale of a Phase…

Elana Gotkine WEDNESDAY, Dec. 21, 2022 (HealthDay News) -- The highest incidence rates of bladder cancer are seen in the Northeast, while the West has the highest deaths rates for prostate cancer among…

MIAMI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, today announced that updated clinical…

BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrates encouraging composite response rates in SCNC (33%) and adenocarcinoma (21%) cohorts Company plans to continue evaluation of BXCL701 combination as potentially differentiated approach for…

ASCO GU Presentation Highlight Nonclinical Data of Next-Generation Androgen Biosynthesis Inhibitor, PRL-02, for Treatment of Advanced Prostate Cancer Company Senior Management Available for One-on-One Investor Meetings at LifeSci…